Comparative Analysis of Development,Revision and Management for Plant Medicines Standards between Chinese Pharmacopeia Commission and United States Pharmacopeia Commission

WANG Xu

doi:10.11653/syfj2013090363

您当前的位置：

首页 >

文章列表页 >

Comparative Analysis of Development,Revision and Management for Plant Medicines Standards between Chinese Pharmacopeia Commission and United States Pharmacopeia Commission

更新时间：2024-09-23

- Comparative Analysis of Development,Revision and Management for Plant Medicines Standards between Chinese Pharmacopeia Commission and United States Pharmacopeia Commission
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 9, Pages: 363-365(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2013090363
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
WANG Xu. Comparative Analysis of Development,Revision and Management for Plant Medicines Standards between Chinese Pharmacopeia Commission and United States Pharmacopeia Commission[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(9): 363-365.
DOI：

WANG Xu. Comparative Analysis of Development,Revision and Management for Plant Medicines Standards between Chinese Pharmacopeia Commission and United States Pharmacopeia Commission[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(9): 363-365. DOI： 10.11653/syfj2013090363.

摘要

探讨中美药典植物药标准制修订的差异

对我国中药标准的修订提出合理建议。通过分析比较中美两国植物药标准修订的现状

提出《中国药典》标准提高应加强基础研究;注重分析方法整体性和系列品种的协调和统一;应用植物药对照提取物(或对照制剂)

解决色谱鉴别规范化和分析一致性的难点;重视整体药物的安全性

注重检测方法的选择;建议借鉴美国低成本高效率的起草修订标准经验及品种负责人负责制的管理模式和理念。中药标准制修订可借鉴美国植物药制修订管理中先进经验

为我国植物药发展提供参考。

Abstract

To investigate difference between Chinese pharmacopeia commission(ChP) and United States Pharmacopeia commission(USP) at enacting and revising plant medicines standards

and suggest reasonable proposals to revision of standards for Chinese medicine in China.By analyze the current situation of standards revision in USA and China

basic research of standards in "Chinese Pharmacopeia" should be improved;Focus on coordination and harmonization of series of varieties and wholeness of analysis methods;Difficulty of analysis consistency and chromatography normalization could be solved by applying control extract of botanicals or the control preparation;Pay high attention to the overall safety of drugs and choice of detection methods;We recommended to learn from USP

such as experience of drafting revised standards with low-cost

management model and philosophy of varieties of responsible person system.Found out insufficient in ChP by analyzing difference between ChP and USP

these advanced experience in USP should be mirrored and shifted to ChP

in order to provide a reference for development of our botanical drugs.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparative Analysis of Development,Revision and Management for Plant Medicines Standards between Chinese Pharmacopeia Commission and United States Pharmacopeia Commission

Related Author

WANG Xu

Related Institution

Chinese Pharmacopeia Commission

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰